Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.34 |
| ▸ | RORC | P51449 | 5/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28998178 | 0.86 | BCL2 (0.41) | MAPK14NAMPTPRMT1MAPKAPK2RORC | |
| SCHEMBL28998186 | 0.83 | CYP17A1 (0.45) | MAPK14NAMPTPRMT1BCL2CYP17A1 | |
| SCHEMBL29153849 | 0.81 | MAPK14 (0.36) | MAPK14NAMPTPRMT1MAPKAPK2RORC | |
| SCHEMBL24867893 | 0.81 | MAPK14 (0.38) | MAPK14NAMPTMAPKAPK2RORCBCL2 | |
| SCHEMBL28998169 | 0.81 | GSK3B (0.37) | NAMPTMAPKAPK2BCL2GSK3BDYRK1A | |
| SCHEMBL28998741 | 0.79 | RAB9A (0.50) | — | |
| SCHEMBL28998161 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL28998228 | 0.77 | CYP17A1 (0.35) | RORCCYP17A1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL28998246 | 0.77 | MEN1 (0.31) | — | |
| SCHEMBL28998255 | 0.76 | BACE1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | disclosed |